SHANGHAI, Dec. 7, 2025 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced today announced with great pleasure that its independently developed fully human BCMA-targeted CAR-T product, zevorcabtagene autoleucel (zevor-cel, R&D code: CT053), has been included in China's Commercial Health Insurance Innovative Drug Catalogue (2025) (referred to as the "Innovative Drug Catalogue") for the treatment of relapsed/refractory multiple myeloma. The Innovative Drug Catalogue was released today at
HONG KONG, Dec. 7, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the successful inclusion of all five of the Company's self-developed innovative drugs into the updated National Reimbursement Drug List (NRDL) for 2025, released by China's National Healthcare Security Administration (NHSA), effective January 1, 2026. These inclusions cover both newly added indications of previously included drugs, and as well as those participating in national reimbursement negotiations for the first time. With these inclusions, all approved indications for Akeso's five
[ 메디채널 김갑성 기자 ] SAN FRANCISCO and SUZHOU, China, Dec. 7, 2025 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that seven of its innovative products have been included in the updated 2025 National Reimbursement Drug List (NRDL). This list features a new indication of TYVYT® (sintilimab injection), and first-time inclusions of SYCUME® (te
SEOUL, South Korea, Dec. 7, 2025 -- Leaders Dental Laboratory, a major force driving the digitalization and large-scale transformation of Korea's dental laboratory industry, is solidifying its leadership with a production facility spanning over 300 pyeong. This extensive infrastructure enables high-volume prosthetics manufacturing and exceptional capability in handling complex clinical cases. By combining state-of-the-art digital equipment with highly skilled dental technicians, the company's clinically integrated collaboration model maximizes both accuracy and efficiency in prosthetic produc
ドバイ(UAE)、2025年12月7日 -- 12月4日、 Cheryはドバイにて2025年アジアユースパラゲームズ(2025 Asian Youth Para Games、AYPG)組織委員会との調印式を開催しました。イベントに臨席したのは、Chery Internationalの副社長であるZhu Shaodong、Asian Paralympic Committeeの会長であるMajid Rashed氏、Dubai Sport Councilの事務局長であるSaeed Hareb氏、DCD and Local Organising Committeeの会長であるThani Juma Berregad氏、そしてAsian Paralympic CommitteeのCEOであるTarek Souei氏など、関係機関/企業の主要な要人たちです。出席者らは共同で、 Cheryが大会の公式独占モビリティ・パートナーとなることを発表しました。「Cheryと共に、生まれながらに高みへ!(With CHERY, Born to Rise!)」をテーマとする今回の提携は、双方のパートナーシップ深化と同時に、Cheryのブランド力と価値観に対する高い評価も示しています。 「飛躍するために生まれた(Born to Rise)」をモットーとする2025 AYPGは、若
[ 메디채널 황정호 기자 ] 두바이, UAE 2025년 12월 7일 -- 체리(Chery)가 12월 4일 두바이에서 2025 아시아청소년장애인경기대회(AYPG) 조직위원회와 파트너십 서명식을 개최했다. 이날 행사에는 주샤오둥(Zhu Shaodong) 체리 인터내셔널(Chery International) 부사장, 마지드 라셰드(Majid Rashed) 아시아패럴림픽위원회(Asian Paralympic Committee) 위원장, 사이드 하렙(Saeed Hareb) 두바이 스포츠평의회(Dubai Sport Council) 사무총장, 타니 주마 베레가드(Thani Juma Berregad) 두바이 장애인클럽(DCD) 회장 겸 AYPG 현지 조직위원장, 타렉 수에이(Tarek Souei) 아시아패럴림픽위원회 CEO 등 주요 인사가 참석했다. 이 자리에서는 체리가 이번 대회의 공식 모빌리티 파트너로 선정됐음이 발표됐다. '체리와 함께, 비상을 위해 태어나다(With CHERY, Born to Rise!)'라는 주제로 한 이번 협업은 양측의 파트너십 강화를 넘어 체리의 브랜드 경쟁력과 가치를 높이 평가했음을 보여준다. '비상을 위해 태어
SHANGHAI, Dec. 6, 2025 -- From December 4 to 7, Assembly Character Toys brand Blokees made its first debut at Brazil Comic Con Experience (CCXP). Blokees exhibited its two major categories "Blokees Model Kits" and "BLOKEES WHEELS", with nearly 60 products based on over 10 world-renowned IPs including Transformers, Jurassic World, Saint Seiya, EVANGELION. At CCXP, the Saint Seiya GALAXY VERSION 03 Gold Zodiac ① was officially announced for a world premiere, meeting the Brazilian market's anticipation. This new set included 9 characters with rich expressions a
SHANGHAI, Dec. 6, 2025 -- Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune diseases, today announced encouraging initial data from an investigator-initiated, first-in-human study of GT801, a T-LNP/mRNA–based in vivo CAR-T candidate targeting CD19. The results were presented in an oral session by Dr. Pin Wang, Chief Scientific Officer of Grit Biotherapeutics, at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. The presentation, titled "Precision In Vivo CAR-T Generation via CLAMP-
런던, 2025년 12월 6일 -- 세계에서 가장 상징적인 스타트업 행사인 4YFN26이 내년 세계이동통신사업자연합회(Global System for Mobile Communications Association, GSMA)의 MWC26 MWC26 바르셀로나(MWC26 Barcelona) 기간 동안 피라 데 바르셀로나(Fira de Barcelona)의 상징적인 그란 비아(Gran Via) 전시장으로 돌아와 2026년 가장 흥미로운 스타트업들의 획기적인 쇼케이스를 진행한다. 수백 개의 출품작 중에서 선정된 2026년 상위 20개 스타트업은 5개 주요 산업 부문에서 가장 빛나는 아이디어와 선도적인 지성들을 선보인다. 4YFN26 어워드(4YFN26 Awards)로 절정에 달하게 될 상위 20개 팀은 최종 우승자가 되기 위해 경쟁하게 된다. 4YFN 상위 20개 팀은 4YFN 바르셀로나 첫날 열리는 4YFN 어워드 준결승(4YFN Awards semifinals)에 참가한다. 이 무대 피칭 경연은 주요 투자자와 업계 전문가로 구성된 패널 앞에서 진행된다. 패널은 혁신성, 확장성, 영향력 등의 기준에 따라 이들을 평가한 후 당일 5개의
アブダビ, 2025年12月6日 -- Abu Dhabi Department of Economic Development(ADDED)が率いるアブダビ経済代表団は、インドとシンガポールへの訪問を成功裏に終え、各分野におけるパートナーシップ強化に向けた協定の締結や機会開拓を行いました。 ADDED議長のAhmed Jasim Al Zaabi閣下は、以下のように述べています。「シンガポールとインドへの訪問は、世界中の主要貿易パートナーや経済大国との関係強化を継続し、国民により明るい未来を保証するための動向と変革に関する議論を主導する中で行われました。影響力のあるパートナーシップは、アブダビのスマートで多様化・持続可能な経済への移行を加速させ、人材、投資家、企業に豊富な機会を生み出す「ファルコン・エコノミー」の重要な柱です。 先進的な政策、ビジネス支援型エコシステム、世界水準のインフラと接続性、そして先見性のある規制を通じて、アブダビは野心と機会が交わる地となりました。 首長国の独自の魅力に惹かれ、アブダビにおける人材、企業、投資は飛躍的に成長を続けています。」 Al Zaabi閣下は以下のように付け加えました。「2024年、シンガポールのアブダビへの投資は25%増加し、製造業、教育、建設、専門的・科学的・技術的活